CA ATLANTIQUE VENDEE-CCI (CRAV.PA) Fundamental Analysis & Valuation

EPA:CRAV • FR0000185506

Current stock price

145 EUR
0 (0%)
Last:

This CRAV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. CRAV.PA Profitability Analysis

1.1 Basic Checks

  • CRAV had positive earnings in the past year.
  • In the past year CRAV has reported a negative cash flow from operations.
  • CRAV had positive earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CRAV reported negative operating cash flow in multiple years.
CRAV.PA Yearly Net Income VS EBIT VS OCF VS FCFCRAV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.26%, CRAV is doing worse than 92.45% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 1.96%, CRAV is doing worse than 92.45% of the companies in the same industry.
Industry RankSector Rank
ROA 0.26%
ROE 1.96%
ROIC N/A
ROA(3y)0.27%
ROA(5y)0.33%
ROE(3y)2.14%
ROE(5y)2.67%
ROIC(3y)N/A
ROIC(5y)N/A
CRAV.PA Yearly ROA, ROE, ROICCRAV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

1.3 Margins

  • With a Profit Margin value of 16.18%, CRAV is not doing good in the industry: 74.53% of the companies in the same industry are doing better.
  • CRAV's Profit Margin has improved in the last couple of years.
  • CRAV does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 16.18%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-9.6%
PM growth 5Y7.85%
GM growth 3YN/A
GM growth 5YN/A
CRAV.PA Yearly Profit, Operating, Gross MarginsCRAV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CRAV.PA Health Analysis

2.1 Basic Checks

  • CRAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CRAV remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for CRAV remains at a similar level compared to 5 years ago.
  • CRAV has a better debt/assets ratio than last year.
CRAV.PA Yearly Shares OutstandingCRAV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
CRAV.PA Yearly Total Debt VS Total AssetsCRAV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • A Debt/Equity ratio of 0.07 indicates that CRAV is not too dependend on debt financing.
  • With an excellent Debt to Equity ratio value of 0.07, CRAV belongs to the best of the industry, outperforming 89.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC5.68%
CRAV.PA Yearly LT Debt VS Equity VS FCFCRAV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CRAV.PA Yearly Current Assets VS Current LiabilitesCRAV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRAV.PA Growth Analysis

3.1 Past

  • The earnings per share for CRAV have decreased by -0.13% in the last year.
  • CRAV shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.22% yearly.
  • The Revenue has decreased by -6.35% in the past year.
  • Measured over the past years, CRAV shows a small growth in Revenue. The Revenue has been growing by 2.17% on average per year.
EPS 1Y (TTM)-0.13%
EPS 3Y-13.64%
EPS 5Y10.22%
EPS Q2Q%26.05%
Revenue 1Y (TTM)-6.35%
Revenue growth 3Y-4.52%
Revenue growth 5Y2.17%
Sales Q2Q%-4.93%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRAV.PA Yearly Revenue VS EstimatesCRAV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

Find the best growth stocksShow best growing peers

1

4. CRAV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • CRAV is valuated correctly with a Price/Earnings ratio of 12.52.
  • Based on the Price/Earnings ratio, CRAV is valued a bit more expensive than the industry average as 72.64% of the companies are valued more cheaply.
  • CRAV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.42.
Industry RankSector Rank
PE 12.52
Fwd PE N/A
CRAV.PA Price Earnings VS Forward Price EarningsCRAV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRAV.PA Per share dataCRAV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1K 2K 3K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)1.23
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. CRAV.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.65%, CRAV has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 4.47, CRAV's dividend is way lower than its industry peers. On top of this 80.19% of the companies listed in the same industry pay a better dividend than CRAV!
  • Compared to an average S&P500 Dividend Yield of 1.81, CRAV pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 2.65%

5.2 History

  • The dividend of CRAV has a limited annual growth rate of 0.59%.
Dividend Growth(5Y)0.59%
Div Incr Years0
Div Non Decr Years0
CRAV.PA Yearly Dividends per shareCRAV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • The dividend of CRAV is growing, but earnings are growing more, so the dividend growth is sustainable.
DP0%
EPS Next 2YN/A
EPS Next 3YN/A
CRAV.PA Yearly Income VS Free CF VS DividendCRAV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

More info and screens

Find the best dividend stocksShow peers with best dividend

CRAV.PA Fundamentals: All Metrics, Ratios and Statistics

CA ATLANTIQUE VENDEE-CCI

EPA:CRAV (4/24/2026, 7:00:00 PM)

145

0 (0%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)02-02
Earnings (Next)04-30
Inst Owners2.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap174.00M
Revenue(TTM)528.17M
Net Income(TTM)85.48M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.65%
Yearly DividendN/A
Dividend Growth(5Y)0.59%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.52
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.04
EV/EBITDA N/A
EPS(TTM)11.58
EY7.99%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-482.01
FCFYN/A
OCF(TTM)-460.29
OCFYN/A
SpS440.14
BVpS3638.97
TBVpS3634.33
PEG (NY)N/A
PEG (5Y)1.23
Graham Number973.722 (571.53%)
Profitability
Industry RankSector Rank
ROA 0.26%
ROE 1.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 16.18%
GM N/A
FCFM N/A
ROA(3y)0.27%
ROA(5y)0.33%
ROE(3y)2.14%
ROE(5y)2.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-9.6%
PM growth 5Y7.85%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 117.76%
Cap/Sales 4.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score4
WACC5.68%
ROIC/WACCN/A
Cap/Depr(3y)170.79%
Cap/Depr(5y)161.51%
Cap/Sales(3y)6.76%
Cap/Sales(5y)6.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.13%
EPS 3Y-13.64%
EPS 5Y10.22%
EPS Q2Q%26.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.35%
Revenue growth 3Y-4.52%
Revenue growth 5Y2.17%
Sales Q2Q%-4.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-351.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-303.43%
OCF growth 3YN/A
OCF growth 5YN/A

CA ATLANTIQUE VENDEE-CCI / CRAV.PA Fundamental Analysis FAQ

What is the fundamental rating for CRAV stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRAV.PA.


What is the valuation status for CRAV stock?

ChartMill assigns a valuation rating of 1 / 10 to CA ATLANTIQUE VENDEE-CCI (CRAV.PA). This can be considered as Overvalued.


Can you provide the profitability details for CA ATLANTIQUE VENDEE-CCI?

CA ATLANTIQUE VENDEE-CCI (CRAV.PA) has a profitability rating of 2 / 10.


What are the PE and PB ratios of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) stock?

The Price/Earnings (PE) ratio for CA ATLANTIQUE VENDEE-CCI (CRAV.PA) is 12.52 and the Price/Book (PB) ratio is 0.04.


Can you provide the dividend sustainability for CRAV stock?

The dividend rating of CA ATLANTIQUE VENDEE-CCI (CRAV.PA) is 4 / 10 and the dividend payout ratio is 0%.